AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.440

+0.6405.42%

Volume:606.89K

Turnover:7.55M

Market Cap:1.56B

PE:11.45

High:12.790

Open:11.740

Low:11.670

Close:11.800

Loading ...

Overview Company News Filings

Neuren Pharmaceuticals Ltd - Type C Meeting Granted by US FDA for Phelan-Mcdermid Syndrome

THOMSON REUTERS

A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Simply Wall St.

Now small investors on the ASX can pull off ‘The Big Short’

Neuren Pharmaceuticals Limited's (ASX:NEU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Simply Wall St.

Here are the top 10 ASX 200 shares today

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching

Simply Wall St.

ASX Market Close: IT stocks drag index lower | January 15, 2025

The Market Herald

Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

Why CAR Group, Myer, Neuren, and Yancoal shares are falling today

Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low

MT Newswires Live

Why these top ASX 200 growth shares could rise 35%+ in 2025

Invest $10,000 into these ASX 200 shares in January

Declining Stock and Solid Fundamentals: Is The Market Wrong About Neuren Pharmaceuticals Limited (ASX:NEU)?

Simply Wall St.

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

Invest $5,000 into these ASX 200 shares in 2025

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

There's more to Australian biotech than just CSL: the opportunities to watch

NewMarket Sets New $500 Million Share Buyback Plan

MT Newswires Live

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

Neuren Pharmaceuticals Says Partner Acadia Completes Sale of Rare Pediatric Disease Priority Review Voucher

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.44,"timestamp":1746166320000,"preClose":11.8,"halted":0,"volume":606889,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":109162108,"shares":125428851,"eps":1.086099,"marketStatus":"Market Closed","change":0.64,"latestTime":"05-02 16:12:00 AEST","open":11.74,"high":12.79,"low":11.67,"amount":7554578,"amplitude":0.094915,"askPrice":12.65,"askSize":17500,"bidPrice":12.38,"bidSize":80,"shortable":3,"etf":0,"ttmEps":1.086099,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746403200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":11.8,"openAndCloseTimeList":[[1746144000000,1746165600000]],"volumeRatio":1.085666,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":109162108,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":1.085666,"shares":125428851,"dividePrice":0,"high":12.79,"amplitude":0.094915,"preClose":11.8,"low":11.67,"week52Low":8.61,"pbRate":"4.29","psRate":"7.20","week52High":24,"institutionHeld":0,"latestPrice":12.44,"committee":-0.990899,"eps":1.086099,"divideRate":0,"volume":606889,"delay":0,"ttmEps":1.086099,"open":11.74,"prevYearClose":12.5,"prevWeekClose":11.34,"prevMonthClose":11.66,"prevQuarterClose":11.93,"fiveDayClose":11.34,"twentyDayClose":11.35,"sixtyDayClose":13.18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509781472","title":"Neuren Pharmaceuticals Ltd -  Type C Meeting Granted by US FDA for Phelan-Mcdermid Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509781472?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876531,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2509458992","title":"A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509458992","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509458992?lang=en_us&edition=fundamental","pubTime":"2025-02-06 11:35","pubTimestamp":1738812902,"startTime":"0","endTime":"0","summary":"Key Insights The projected fair value for Neuren Pharmaceuticals is AU$13.55 based on 2 Stage Free Cash Flow to Equity...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/a-look-at-the-fair-value-of-neuren-pharmaceuticals-limited-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TV","BK4109","BK4211","NEU","NEU.AU","BK4100","BK7096","DCF","BK7508","FCF"],"gpt_icon":0},{"id":"2508154456","title":"Now small investors on the ASX can pull off ‘The Big Short’","url":"https://stock-news.laohu8.com/highlight/detail?id=2508154456","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508154456?lang=en_us&edition=fundamental","pubTime":"2025-02-03 07:39","pubTimestamp":1738539553,"startTime":"0","endTime":"0","summary":"One of the greatest recent films on share markets was The Big Short which was released in 2015.Starring Steve Carell, it did a fairly good job of explaining how shorting works and in particular how gathering information on the sort of junk property loans that were then being written in the US and collected together in highly rated collateralised debt obligations  helped to bring about the global financial crisis.It also showed how investors such as Michael Burry  and Mark Baum  could dramatically profit from shorting stocks – making money by selling shares and buying them back later at a cheaper price.One potential answer has arrived in the form of a new exchange-traded fund that will actively identify and short ASX-listed companies.Developed by VanEck and known as the VanEck Australian Long Short Complex ETF , the aim of what is effectively a listed hedge fund offering without the high initial investment hurdle is to outperform the ASX 200 by selecting a concentrated portfolio of what","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/The-Big-Short-ASX-ALFA-VanEck.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/The-Big-Short-ASX-ALFA-VanEck.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/small-investors-asx-can-pull-off-the-big-short/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["JBH.AU","BK7096","BK7508","BK4588","FDN","BK7001","BK4585","ALF.AU","NEU.AU","ALFA.AU","BK4550"],"gpt_icon":0},{"id":"2505758190","title":"Neuren Pharmaceuticals Limited's (ASX:NEU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505758190","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505758190?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:02","pubTimestamp":1737507736,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals'  stock is up by a considerable 13% over the past week. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Neuren Pharmaceuticals'  ROE today.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Neuren Pharmaceuticals is:. First thing first, we like that Neuren Pharmaceuticals has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 13% which is quite remarkable. Under the circumstances, Neuren Pharmaceuticals' considerable five year net income growth of 81% was to be expected.Neuren Pharmaceuticals doesn't pay","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuren-pharmaceuticals-limiteds-asx-neu-010216939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4109","NEU.AU","BK7508","BK7096","NEU"],"gpt_icon":0},{"id":"2503324079","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2503324079","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503324079?lang=en_us&edition=fundamental","pubTime":"2025-01-16 14:00","pubTimestamp":1737007202,"startTime":"0","endTime":"0","summary":"It was a jubilant Thursday session for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, giving investors some much-needed relief. After a shaky week, the ASX 200 wasn't holding back today a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/16/here-are-the-top-10-asx-200-shares-today-565/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["KAR.AU","JHX.AU","BK7125","ZIP.AU","BK7096","CTD.AU","BK7161","BK7078","NEU.AU","RMS.AU","TAH.AU","PNI.AU","BK7506","BK7044","KLS.AU","BK7104","XJO.AU","BK7093","BK7142","EMR.AU","BK7070","BK7508","BK7062"],"gpt_icon":0},{"id":"2503689604","title":"Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching","url":"https://stock-news.laohu8.com/highlight/detail?id=2503689604","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503689604?lang=en_us&edition=fundamental","pubTime":"2025-01-16 04:00","pubTimestamp":1736971232,"startTime":"0","endTime":"0","summary":"Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/heres-why-we-think-neuren-pharmaceuticals-asxneu-is-well-wor","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","NEU.AU","EBIT","BK7508","BK4109","NEU"],"gpt_icon":0},{"id":"2503661411","title":"ASX Market Close: IT stocks drag index lower | January 15, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503661411","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503661411?lang=en_us&edition=fundamental","pubTime":"2025-01-15 14:01","pubTimestamp":1736920860,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.22% at 8,213 points.The local bourse gave up early gains and slipped into the red in afternoon trade, and did not return to positive territory.The Discretionary sector was the best performer, up 0.2%, followed by Real Estate, 0.13%. IT was the biggest loser, down 1.25%, followed by Telecommunication, down 1.2% and Industrials, down 0.65%.Gold Mountain closed up 50% after announcing drill targets for its Salinas II Project in Brazil.D3 Energyfinished the session up 23.1% on results from initial production testing from its major borehole in South Africa’s Free State Province. The test reported an average gas flow rate of 102,000 standard cubic feet per day over the first seven days.Arafura Rare Earths closed up 17.4% after further government support for its Nolans project with the signing of a binding term sheet for $200M with the NRFC. The company says the receipt of the convertible notes is a “key milestone” in its strategy of securing government seeded funds.H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-it-stocks-drag-index-lower-january-15-2025-2025-01-15/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NEU.AU","BK7142","TLS.AU","D3E.AU","GMN.AU","BK4588","BK7096","BK7104","BK7095","BK7508","BK7511","HRZ.AU","BK7042","MAA","ARU.AU","BK4215","BK4585"],"gpt_icon":0},{"id":"2503654658","title":"Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503654658","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503654658?lang=en_us&edition=fundamental","pubTime":"2025-01-15 11:21","pubTimestamp":1736911289,"startTime":"0","endTime":"0","summary":"After a strong start to the morning's trade, things don't look so upbeat for the S&P/ASX 200 Index  this afternoon. At the time of writing, the ASX 200 has given up most of its early lead today, and is sitting pretty much flat at 8,226 points. But let's talk about one ASX 200 healthcare stock that is plunging in value.That ASX 200 healthcare stock is none other than Neuren Pharmaceuticals Ltd .Yesterday, Neuren shares closed at a flat $12 each. This morning, those same shares opened at $12.03 but quickly started dropping. At the time of writing, the ASX 200 healthcare stock has lost a horrid 8.83% and is down to just $10.94 a share. That's after going as low as $10.90 this afternoon.Well, it appears that this steep sell-off is a consequence of an ASX announcement Neuren made to investors this morning just before market open.After today's share price plunge, this ASX 200 healthcare stock is down a painful 53.6% over the past 12 months. Investors will no doubt hope for a turnaround over ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/15/why-did-this-1-4-billion-asx-200-healthcare-stock-just-dive-9/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2503650118","title":"Why CAR Group, Myer, Neuren, and Yancoal shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2503650118","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503650118?lang=en_us&edition=fundamental","pubTime":"2025-01-15 11:12","pubTimestamp":1736910744,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is running out of steam and fighting hard to stay in positive territory. In afternoon trade, the benchmark index is up slightly to 8,230.9 points. Four ASX shares that a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/15/why-car-group-myer-neuren-and-yancoal-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CAR.AU","BK7503","BK4585","BK4139","BK7002","YAL.AU","MAA","NEU.AU","XJO.AU","MYR.AU","BK7153","BK7096","BK4215","LU2065169927.USD","ACAD","BK7083","LU2065170008.USD","BK7509","BK7508","LU2065171311.SGD","LU2065171402.SGD","BK7029","CAR","BK4588"],"gpt_icon":0},{"id":"2503679634","title":"Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2503679634","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503679634?lang=en_us&edition=fundamental","pubTime":"2025-01-15 08:41","pubTimestamp":1736901677,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals'  partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.The application is expected to be approved in the first quarter of 2026, the filing said.Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2503254561","title":"Why these top ASX 200 growth shares could rise 35%+ in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503254561","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503254561?lang=en_us&edition=fundamental","pubTime":"2025-01-14 09:30","pubTimestamp":1736818200,"startTime":"0","endTime":"0","summary":"] Digital Realty recently reported a record sales quarter during which it sold double the data centre capacity of its previous high and about four times more capacity than it usually sells in a quarter. This reinforces our view that the significant demand for cloud computing and AI-related digital infrastructure is going to unpin attractive returns and long-term growth. […] Our preferred exposure is NEXTDC. It has 17 operational data centres in Australia and nearly a dozen under construction or about to be built across Australasia and Asia.  Morgans currently has an add rating and $20.50 price target on its sha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/14/why-these-asx-200-growth-shares-could-rise-35-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7503","BK7043","NEU.AU","NXT.AU","BK7096"],"gpt_icon":0},{"id":"2501144245","title":"Invest $10,000 into these ASX 200 shares in January","url":"https://stock-news.laohu8.com/highlight/detail?id=2501144245","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501144245?lang=en_us&edition=fundamental","pubTime":"2025-01-06 05:25","pubTimestamp":1736112325,"startTime":"0","endTime":"0","summary":"Do you have $10,000 to invest into ASX 200 shares in January?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/06/invest-10000-into-these-asx-200-shares-in-january/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1668664300.SGD","IE0002270589.USD","BK7016","LU0106831901.USD","LU2237443382.USD","IE00B19Z3B42.SGD","BK7503","BK4127","LU2237438978.USD","BK4585","BK7096","BK4550","LU2237443465.HKD","LU2237443978.SGD","IE00BSNM7G36.USD","LU2237443622.USD","BK4588","XRO.AU","NEU.AU","BK4516","IE0004086264.USD","IE0004091025.USD","BK4533","TAM.AU","LU2237443895.HKD","LU2237443549.SGD","IE00B19Z3581.USD","LU1791807156.HKD","BK7508","IE00BFXG1179.USD","BK7104","IE0034235188.USD","BK4504","BK4552"],"gpt_icon":1},{"id":"2494595016","title":"Declining Stock and Solid Fundamentals: Is The Market Wrong About Neuren Pharmaceuticals Limited (ASX:NEU)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2494595016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494595016?lang=en_us&edition=fundamental","pubTime":"2024-12-25 09:43","pubTimestamp":1735091005,"startTime":"0","endTime":"0","summary":"With its stock down 12% over the past three months, it is easy to disregard Neuren Pharmaceuticals (ASX:NEU). However...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/declining-stock-and-solid-fundamentals-is-the-market-wrong-a-1444","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK7096","BK7508","NEU","BK4109"],"gpt_icon":1},{"id":"2492391510","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2492391510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492391510?lang=en_us&edition=fundamental","pubTime":"2024-12-18 05:51","pubTimestamp":1734472274,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUE5ZBLKN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2492254766","title":"Invest $5,000 into these ASX 200 shares in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492254766","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492254766?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:41","pubTimestamp":1734385260,"startTime":"0","endTime":"0","summary":"If you are fortunate enough to have $5,000 spare to invest into ASX 200 shares, then read on. That's because listed below are three shares that analysts are tipping as top buys for the year ahead. Her","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/17/invest-5000-into-these-asx-200-shares-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4550","BK4552","LU1668664300.SGD","LU2237438978.USD","DMP.AU","LU2237443978.SGD","IE0004091025.USD","BK4504","IE00BFXG1179.USD","BK4516","IE0004086264.USD","BK4588","BK4127","BK7508","TWE.AU","LU2237443382.USD","BK7097","BK4585","IE00BSNM7G36.USD","NEU.AU","LU1791807156.HKD","IE0002270589.USD","BK4533","LU2237443465.HKD","LU2237443622.USD","IE00B19Z3B42.SGD","LU2237443895.HKD","BK7137","LU0106831901.USD","BK7096","IE00B19Z3581.USD","IE0034235188.USD","BK7505","LU2237443549.SGD"],"gpt_icon":0},{"id":"2491018345","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2491018345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491018345?lang=en_us&edition=fundamental","pubTime":"2024-12-16 06:13","pubTimestamp":1734300824,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241215:nTUE2CXFCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7007","SNT.AU","BK7096","XJO.AU","SGXZ23171101.USD","BOT.AU","BK7502","BK7067","BK7501","CSL.AU","DXB.AU","LU1169589451.USD","CSL","IMM.AU","CVB.AU","BK7511","LU1169590202.USD","TLX.AU","BK4086","NEU.AU","SG9999004303.SGD","LU0728928796.USD","BK7508","XAO.AU","OPT.AU","XKO.AU"],"gpt_icon":0},{"id":"2491363592","title":"NewMarket Sets New $500 Million Share Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2491363592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491363592?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:35","pubTimestamp":1734042953,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) said late Thursday it received board approval for a new share repurchase program for up to $500 million of its common stock.The new program runs until Dec. 31, 2027, and replaces the c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4109","BK7096","NEU","NEU.AU"],"gpt_icon":0},{"id":"2491357057","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2491357057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491357057?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:55","pubTimestamp":1734040525,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUE6BCHYJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2490479817","title":"Neuren Pharmaceuticals Says Partner Acadia Completes Sale of Rare Pediatric Disease Priority Review Voucher","url":"https://stock-news.laohu8.com/highlight/detail?id=2490479817","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490479817?lang=en_us&edition=fundamental","pubTime":"2024-12-12 08:07","pubTimestamp":1733962077,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its Nasdaq-listed partner Acadia Pharmaceuticals completed the sale of a rare pediatric disease priority review voucher for $150 million, according to a Thursday filing with the Australian bourse.The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.The company is entitled to one-third of the proceeds under its license agreement with Acadia, according to the filing.Price : $13.42, Change: $-0.02, Percent Change: -0.15%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","LU1043141123.HKD","LU0994945656.USD","AUD","BK7096","BK4231","BK4125","LU0345774631.USD","LU0426417589.USD","LU2238339852.HKD","NEU.AU","AKR","LU0426412945.USD","BK4080"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":97,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[]}}